{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:06:29Z","timestamp":1790215589805,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T00:00:00Z","timestamp":1619049600000},"content-version":"am","delay-in-days":386,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001665","name":"French National Research Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.ijantimicag.2020.105912","type":"journal-article","created":{"date-parts":[[2020,1,25]],"date-time":"2020-01-25T11:35:16Z","timestamp":1579952116000},"page":"105912","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["Whole-genome sequencing in drug susceptibility testing of Mycobacterium tuberculosis in routine practice in Lyon, France"],"prefix":"10.1016","volume":"55","author":[{"given":"Charlotte","family":"Genestet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Hodille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6337-3715","authenticated-orcid":false,"given":"Jean-Luc","family":"Berland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Ginevra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9535-4925","authenticated-orcid":false,"given":"Juliet E.","family":"Bryant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Ader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rard","family":"Lina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oana","family":"Dumitrescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2020.105912_bib0001","series-title":"Global tuberculosis report 2019","year":"2019"},{"key":"10.1016\/j.ijantimicag.2020.105912_bib0002","series-title":"WHO treatment guidelines for isoniazid-resistant tuberculosis: supplement to the WHO treatment guidelines for drug-resistant tuberculosis","year":"2018"},{"key":"10.1016\/j.ijantimicag.2020.105912_bib0003","article-title":"Role of disputed mutations in the rpoB gene in interpretation of automated liquid MGIT culture results for rifampin susceptibility testing of Mycobacterium tuberculosis","volume":"56","author":"Miotto","year":"2018","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2020.105912_bib0004","first-page":"154","article-title":"Mycobacterium tuberculosis drug-resistance testing: challenges, recent developments and perspectives","volume":"23","author":"Sch\u00f6n","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2020.105912_bib0005","first-page":"1403","article-title":"Prediction of susceptibility to first-line tuberculosis drugs by DNA sequencing","volume":"379","author":"Allix-B\u00e9guec","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2020.105912_bib0006","first-page":"300","article-title":"Potential for erroneous results indicating resistance when using the Bactec MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide","volume":"48","author":"Chedore","year":"2010","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2020.105912_bib0007","article-title":"Practice guidelines for clinical microbiology laboratories: mycobacteria","volume":"31","author":"Forbes","year":"2018","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2020.105912_bib0008","article-title":"Evaluation of whole-genome sequencing for mycobacterial species identification and drug susceptibility testing in a clinical setting: a large-scale prospective assessment of performance against line probe assays and phenotyping","volume":"56","author":"Quan","year":"2018","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2020.105912_bib0009","first-page":"82","article-title":"Evaluation of whole genome sequencing and software tools for drug susceptibility testing of Mycobacterium tuberculosis","volume":"25","author":"van Beek","year":"2019","journal-title":"Clin Microbiol Infect"},{"issue":"7","key":"10.1016\/j.ijantimicag.2020.105912_bib0010","first-page":"116","author":"Guthmann","year":"2017","journal-title":"Bull Epid\u00e9miol Hebd"},{"key":"10.1016\/j.ijantimicag.2020.105912_bib0011","first-page":"1428","article-title":"Simplified acetylcysteine-alkali digestion-decontamination procedure for isolation of mycobacteria from clinical specimens","volume":"25","author":"Ratnam","year":"1987","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2020.105912_bib0012","first-page":"363","article-title":"Rapid susceptibility testing of Mycobacterium tuberculosis by the Mycobacteria Growth Indicator Tube (MGIT AST SIRE)","volume":"6","author":"Macondo","year":"2000","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2020.105912_bib0013","first-page":"938","article-title":"Mycobacterial growth indicator tube versus the proportion method on L\u00f6wenstein\u2013Jensen medium for antibiotic susceptibility testing of Mycobacterium tuberculosis","volume":"19","author":"Cambau","year":"2000","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.105912_bib0014","first-page":"1908","article-title":"PhyResSE: a web tool delineating Mycobacterium tuberculosis antibiotic resistance and lineage from whole-genome sequencing data","volume":"53","author":"Feuerriegel","year":"2015","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2020.105912_bib0015","first-page":"589","article-title":"Prospective whole-genome sequencing in tuberculosis outbreak investigation, France, 2017\u20132018","volume":"25","author":"Genestet","year":"2019","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.105912_bib0016","article-title":"How well do routine molecular diagnostics detect rifampin heteroresistance in Mycobacterium tuberculosis?","volume":"57","author":"Ng","year":"2019","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2020.105912_bib0017","series-title":"High-priority target product profiles for new tuberculosis diagnostics","year":"2014"},{"key":"10.1016\/j.ijantimicag.2020.105912_bib0018","first-page":"1741","article-title":"Evaluation of whole-genome sequence method to diagnose resistance of 13 anti-tuberculosis drugs and characterize resistance genes in clinical multi-drug resistance Mycobacterium tuberculosis isolates from China","volume":"10","author":"Chen","year":"2019","journal-title":"Front Microbiol"},{"key":"10.1016\/j.ijantimicag.2020.105912_bib0019","first-page":"44","article-title":"Dissecting whole-genome sequencing-based online tools for predicting resistance in Mycobacterium tuberculosis: can we use them for clinical decision guidance?","volume":"110","author":"Macedo","year":"2018","journal-title":"Tuberc (Edinb)"},{"key":"10.1016\/j.ijantimicag.2020.105912_bib0020","first-page":"358","article-title":"embB306 mutations as molecular indicators to predict ethambutol susceptibility in Mycobacterium tuberculosis","volume":"58","author":"Sirgel","year":"2012","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ijantimicag.2020.105912_bib0021","first-page":"1061","article-title":"Mutations at embB codon 306 are an important molecular indicator of ethambutol resistance in Mycobacterium tuberculosis","volume":"53","author":"Starks","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.105912_bib0022","first-page":"4447","article-title":"Novel mutations within the embB gene in ethambutol-susceptible clinical isolates of Mycobacterium tuberculosis","volume":"48","author":"Lee","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.105912_bib0023","first-page":"762","article-title":"New epidemic cluster of pre-extensively drug resistant isolates of Mycobacterium tuberculosis Ural family emerging in Eastern Europe","volume":"19","author":"Sinkov","year":"2018","journal-title":"BMC Genomics"},{"key":"10.1016\/j.ijantimicag.2020.105912_bib0024","first-page":"291","article-title":"Prevention of false resistance results obtained in testing the susceptibility of Mycobacterium tuberculosis to pyrazinamide with the Bactec MGIT 960 system using a reduced inoculum","volume":"51","author":"Piersimoni","year":"2013","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2020.105912_bib0025","first-page":"1920","article-title":"Non-pncA gene-mutated but pyrazinamide-resistant Mycobacterium tuberculosis: why is that?","volume":"55","author":"Werngren","year":"2017","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2020.105912_bib0026","first-page":"1871","article-title":"Comprehensive whole-genome sequencing and reporting of drug resistance profiles on clinical cases of Mycobacterium tuberculosis in New York State","volume":"55","author":"Shea","year":"2017","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2020.105912_bib0027","first-page":"659","article-title":"Turnaround time of whole genome sequencing for mycobacterial identification and drug susceptibility testing in routine practice","volume":"24","author":"Olaru","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2020.105912_bib0028","article-title":"Whole-genome sequencing of Mycobacterium tuberculosis for rapid diagnostics: feasibility of a decentralised model","volume":"4","author":"Martinez","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ijantimicag.2020.105912_bib0029","first-page":"49","article-title":"Rapid, comprehensive, and affordable mycobacterial diagnosis with whole-genome sequencing: a prospective study","volume":"4","author":"Pankhurst","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ijantimicag.2020.105912_bib0030","first-page":"1350","article-title":"Outbreak of multidrug-resistant tuberculosis in South Africa undetected by WHO-endorsed commercial tests: an observational study","volume":"18","author":"Makhado","year":"2018","journal-title":"Lancet Infect Dis"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920300510?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920300510?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:34:50Z","timestamp":1760376890000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857920300510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S0924857920300510"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105912","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Whole-genome sequencing in drug susceptibility testing of Mycobacterium tuberculosis in routine practice in Lyon, France","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105912","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105912"}}